A California jury awarded $29 million to a woman who said abestos in Johnson & Johnson’s talcum-powder-based products caused her cancer.
Pfizer Inc. received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at the company’s Meridian Medical Technologies site.
Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.
A Missouri Supreme Court ruling on talc lawsuits could reduce the liability and number of large trials Johnson & Johnson faces over allegations the company’s talc products, including baby powder, cause cancer.
The U.S. Supreme Court rejected Maryland’s bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs.
Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Action Lawsuits
Despite a decline over the past year of class action lawsuits, life science companies remain a popular target for securities fraud litigation.
A U.S. judge threw out the state of Maryland’s bid to protect the healthcare law known as Obamacare in a ruling that also sidestepped a decision on whether President Donald Trump’s appointment of Matthew Whitaker as acting attorney general was lawful.
The one-time billionaire founder of Insys Therapeutics Inc. and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.
UnitedHealth Group’s Optum unit is suing David Smith, a former information technology executive, for breach of contract.